GenScript and Twist join Eli Lilly's TuneLab AI platform
On 16–17 September 2026, GenScript Biotech and Twist Bioscience both joined Lilly TuneLab, a collaborative AI-based drug discovery platform. GenScript is contributing large-scale wet-lab validation and Twist antibody characterisation data to TuneLab's models.
Who is affected and how
- pharmaceuticals
- Under the TuneLab model, contract partners supplying experimental data become integral parts of AI platforms, which matters when selecting CRO partners.
Sources
- GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly's AI/ML Drug Discovery Platform - Insight, China's Pharmaceutical Industryflcube.com · Sep 17, 2026
- Anthropic builds wet lab for AI-driven drug discoveryquartz · Sep 18, 2026
- Anthropic Confirms Wet Lab as AI Drug Research Push Expandsmexico business news · Sep 18, 2026
- Anthropic sets up biology lab to expand AI drug researchthe news international · Sep 18, 2026
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuterscnbc.com · Sep 18, 2026
- Exclusive-Anthropic quietly sets up biology lab as it ramps AI drug program By Reutersinvesting.com · Sep 18, 2026
- Anthropic sets up Bay Area wet lab for AI drug research - Cryptopolitancryptopolitan.com · Sep 18, 2026
- AI in Drug Discovery: From Lab Prediction to Clinical Proofworld health expo (whx) · Sep 20, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.